Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Official title

Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Trial of Cryocompression With or Without Cilostazol

Overview

The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cryocompression is a therapy that combines compression garments or dressings with cooling of the treated area. Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs. Giving cilostazol together with cryocompression may be safe and tolerable in treating patients with gynecological cancers.

Detailed description

PRIMARY OBJECTIVES:

I. To quantify the incidence and severity of peripheral neuropathy in women treated with paclitaxel for gynecologic malignancies in conjunction with cryocompression and to assess the impact of cilostazol on the development of peripheral neuropathy. (ARM A and ARM B) II. To quantify the baseline post-chemotherapy neuropathy rates among patients with gynecologic malignancies following standard clinical care practices according to their treating physician. (ARM C)

SECONDARY OBJECTIVES:

I. To estimate the potential impact of cilostazol on quality of life related to chemotherapy-induced peripheral neuropathy.

II. To estimate the potential impact of cilostazol on the need for pharmacologic symptom management for peripheral neuropathy.

III. To estimate the potential impact of cilostazol on chemotherapy dose reductions and delays due to peripheral neuropathy.

IV. To assess the safety of using cilostazol in conjunction with chemotherapy regimens with platinum/paclitaxel with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy.

OUTLINE: Participants are assigned to 1 of 3 arms.

ARM A: Patients receive paclitaxel infusion once daily (QD) and receive cryocompression therapy with cooling compression wraps three times daily (TID) over 15 minutes before, during, and after receiving paclitaxel infusion on day 1 of each cycle. Patients also receive cilostazol orally (PO) twice daily (BID) beginning with their first paclitaxel infusion continuing until 2 weeks after the final paclitaxel infusion. Treatment with paclitaxel continues for up to 6-9 cycles in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive paclitaxel infusions QD and receive cryocompression therapy with cooling compression wraps TID for 15 minutes before, during, and after receiving paclitaxel infusions on day 1 of each cycle. Treatment with paclitaxel continues for up to 6-9 cycles in the absence of disease progression or unacceptable toxicity.

ARM C: Patients undergo standard of care throughout the study.

After completion of study treatment, patients are followed up at 30 days and then up to 1 year.

Interventions

• Other Best Practice
  Undergo standard of care
• Drug Cilostazol
  Given PO
• Device Cryocompression Therapy
  Undergo cryocompression therapy
• Drug Paclitaxel
  Given by infusion
• Other Quality-of-Life Assessment
  Ancillary studies

Primary outcome measures

• Difference in sensation and vibration objective neuropathy scores (Arms A and B) [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]
• Rates of impaired sensation and vibration on objective neuropathy testing and ≥ Grade 2 neuropathy among patients who recently completed paclitaxel treatment with standard of care treatment protocols (Arm C) [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]

Secondary outcome measures (6)

• Difference in sensation and vibration objective neuropathy scores [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]
• Difference in >= grade 2 neuropathy between the two study arms [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]
• Changes in Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-NTX) scores [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]
• Differences in the rate of patients starting new pharmacologic therapy for peripheral neuropathy while receiving paclitaxel chemotherapy [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]
• Differences in the rate of patients requiring paclitaxel dose reductions or chemotherapy delays due to peripheral neuropathy [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]
• Rate of grade 3 adverse events [Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months]

Eligibility criteria

Inclusion criteria

• INCLUSION CRITERIA FOR ARMS A and B:
• Age 18 years or older
• Diagnosis of uterine, ovarian/fallopian tube/primary peritoneal, cervical, or vulvar cancer and planned chemotherapy regimen of 6-9 cycles of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy
• Eastern Cooperative Oncology Group performance status from 0 to 2
• ARM C: Age 18 years or older
• ARM C: Diagnosis of uterine, ovarian/fallopian tube/primary peritoneal, cervical, or vulvar cancer and completion of 6-9 cycles of a chemotherapy regimen consisting of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy within the last 3 months
• ARM C: Eastern Cooperative Oncology Group performance status from 0 to 2

Exclusion criteria

• EXCLUSION CRITERIA FOR ARMS A and B:
• Any patient unable and/or unwilling to cooperate with all study protocols
• Previous treatment with paclitaxel
• Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment
• Diabetes mellitus with hemoglobin A1c >7.0
• Hepatic impairment, moderate to severe (Class B \& C by Child-Pugh score)

• Slight or moderate malignant ascites alone will not be considered indicative of hepatic impairment in the absence of other evidence of hepatic disease
• Raynaud's phenomenon
• Active wounds on the hands or feet
• High risk uncontrolled arrhythmias
• Ischemic heart disease
• Inadequate bone marrow function with white blood count < 4,000/mm\^3 and platelet count < 100,000/mm\^3
• Inadequate liver function with serum total bilirubin >= 1.5mg/dL
• Inadequate renal function with serum creatinine >= 1.5mg/dL
• On one or more antiplatelet therapies excluding acetylsalicylic acid
• Hypersensitivity (e.g. anaphylaxis, angioedema) to cilostazol or any components of cilostazol
• Pregnant and nursing patients

• Patients enrolled in this study who have the potential to become pregnant (have an intact uterus, ovary(ies), and fallopian tube(s), have not entered menopause, and have regular menses) are required to utilize reliable contraception such as celibacy, hormonal contraception (oral pills, implant, injection, ring or patch), intrauterine device (IUD), condom and/or diaphragm with spermicide
• Incarcerated patients
• Patients unable to consent for themselves, due to cognitive impairment or other reason
• Patients with contraindications to cilostazol
• Any patient who does not meet criteria to receive chemotherapy
• ARM C: Any patient unable and/or unwilling to cooperate with all study protocols
• ARM C: Previous treatment with paclitaxel
• ARM C: Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment
• ARM C: Diabetes mellitus with hemoglobin A1c >7.0
• ARM C: Pregnant patients
• ARM C: Incarcerated patients
• ARM C: Patients unable to consent for themselves, due to cognitive impairment or other reason

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Supportive care

Study locations

United States · 3 centers

• Emory University Hospital Midtown — Atlanta
• Emory University Hospital/Winship Cancer Institute — Atlanta
• Emory Saint Joseph's Hospital — Atlanta

Identifiers

NCT: NCT06492070 · STUDY00007242 · NCI-2024-03905 · STUDY00007242 · Winship6141-24 · P30CA138292

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗